Skip to main content
Erschienen in: Journal of Ophthalmic Inflammation and Infection 1/2014

Open Access 01.12.2014 | Original research

Macular retinal and choroidal thickness in unilateral relentless placoid chorioretinitis analyzed by swept-source optical coherence tomography

verfasst von: Rosa Dolz-Marco, Álvaro Rodríguez-Ratín, Pablo Hernández-Martínez, Isabel Pascual-Camps, María Andreu-Fenoll, Roberto Gallego-Pinazo

Erschienen in: Journal of Ophthalmic Inflammation and Infection | Ausgabe 1/2014

Abstract

Background

The purpose of this study is to evaluate the retinal and choroidal thickness of the macular region in patients with unilateral relentless placoid chorioretinitis (RPC) and macular involvement. Patients diagnosed with RPC affecting only one eye underwent a comprehensive ophthalmologic examination including best-corrected visual acuity (BCVA), axial length (AL) measurement, slit-lamp examination, and color fundus and autofluorescence photography. The macular region was scanned by swept-source optical coherence tomography in the 1,050-nm wavelength. Automated segmentations of the retina and the choroid were used to obtain the corresponding thickness values.

Results

A total number of three patients (two men and one woman; age range 17 to 62 years) were included. Eyes with clinically evident RPC had a mean AL of 24.62 - 0.11 mm, whereas in the clinically healthy fellow eyes, the mean AL was 24.65 - 0.03 (p?=?0.70). The mean BCVA was 0.93 - 0.16 in eyes with RPC, and 1.0 in all the fellow eyes (p?=?0.70). Slit-lamp examination did not reveal any sign of vitreous inflammation in any cases. The mean macular retinal thickness was 288.10 - 10.22 ?m in eyes with RPC, and 300.30 - 7.17 ?m in the healthy fellow eyes (p?=?0.20). The mean central choroidal thickness was 260.70 - 140.60 ?m in eyes with RPC, and 262.30 - 123.10 ?m in the fellow eyes (p?=?0.99). The mean macular choroidal thickness was 248.60 - 128.40 and 255.10 - 123.60 ?m, respectively (p?=?0.99).

Conclusions

The pathogenesis of RPC remains unknown. No changes in the retinal and choroidal thickness were observed in the macular area of eyes diagnosed with RPC with macular involvement compared with the asymptomatic healthy fellow eyes. Further prospective studies are warranted in order to investigate the role of the choroid in cases of RPC.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12348-014-0024-x) contains supplementary material, which is available to authorized users.

Competing interests

RDM received research grants from Alcon, Allergan, Bayer, Heidelberg Engineering, Novartis, and Thea. RGP is a consultant to Alcon, Bayer, and Novartis and received research grants from Alcon, Allergan, Bayer, Heidelberg Engineering, Novartis, Sensimed, and Thea. The other authors declare that they have no competing interests.

Authors' contributions

All authors have made substantial contributions to conception and design of the study or acquisition, analysis, and interpretation of data; have been involved in drafting the manuscript or revising it critically for important intellectual content; have given final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.
Abkürzungen
3D
Three dimension
AL
Axial length
APMPPE
Acute posterior multifocal placoid pigment epitheliopathy
ETDRS
Standard early treatment of diabetic retinopathy study
OCT
Optical coherence tomography
RPC
Relentless placoid chorioretinitis
SS
Swept-source

Background

Relentless placoid chorioretinitis (RPC), also known as ampiginous choroiditis, was first described by Jones et al. as a particular type of posterior uveitis that shared clinical and angiographic characteristics with acute posterior multifocal placoid pigment epitheliopathy (APMPPE) and serpiginous choroiditis. However, it typically exhibits a prolonged clinical course, with recurrences of the inflammation after months to years following the onset [1]-[3]. The scattered distribution of the multiple, plaque-like, creamy coalescent lesions, affecting simultaneously the posterior pole and the midperipheral retina, usually leads to poor visual outcomes [1].
The etiopathogenesis of RPC remains unknown, but both fluorescein and indocyanine green angiographic findings evidence involvement of the choroid altogether with the typical retinal changes [1]. The analysis of the choroidal morphologic and morphometric features has significantly improved with the development of high-penetrance optical coherence tomography (OCT) devices [4],[5]. The last generation of these integrates the swept-source (SS) laser technology. The SS-OCT is characterized by a light source with a longer wavelength of 1,050 nm. This technical change allows deeper penetration through the ocular tissue, thus obtaining a three-dimensional (3D) high-contrast image of the retina and the choroid [6],[7]. This system has a scanning speed of 100,000 A-scans per second and a scan window depth of 2.6 mm with an axial resolution of 8 mm and a transverse resolution of 20 mm in tissue [8]. In the present study, we evaluated the choroidal thickness of the macular area in patients with unilateral RPC and macular involvement.

Methods

This observational retrospective study evaluated patients diagnosed with macular involvement due to unilateral RPC by a single physician (RGP) according to the previous reports on this disease [1]-[3]. The present study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with the La Fe University and Polytechnic Hospital review board and informed consent regulations.
We performed a comprehensive ophthalmic examination including best-corrected visual acuity (BCVA) using standard early treatment of diabetic retinopathy study (ETDRS) charts (decimal scale), axial length (AL) measurement (IOLMaster 500, Carl Zeiss Meditec, Inc., Dublin, CA, USA), slit-lamp examination, and color fundus and autofluorescence photographs (Visupac, Carl Zeiss Meditec Inc.). The macular region of all patients was scanned with SS-OCT (DRI OCT-1 Atlantis, Topcon, Tokyo, Japan) at a 1,050-nm wavelength with a 3D raster scan protocol. The SS-OCT 3D scan modality produces a retinal and choroidal thickness map of the macular area (12 - 9 mm) after an automated segmentation of the retina and the choroid. The retinal and choroidal thickness maps were overlap to the modified ETDRS grid (6 - 6 mm) to study the different mean values of each sector (Figure 1). The mean thickness of each sector was automatically measured within 500 ?m from the center of the fovea in the central sector; 500 to 1,500 ?m from the center of the fovea in four juxtafoveal or inner sectors (superior, inferior, nasal, and temporal), and 1,500 to 3,000 ?m from the center of the fovea in four extrafoveal or outer sectors (superior, inferior, temporal, and nasal).
All the data were processed and a comparison between the data of the affected eye and the fellow healthy eye was performed. Statistical analysis was performed using Statistical Package for Social Sciences v.20.0 (IBM Corp., Armonk, NY, USA).

Results

Three patients (two men aged 50 and 17 years and one woman aged 62 years) diagnosed with RPC and macular involvement were included (Figures 2, 3, and 4). The time from the onset of visual symptoms related to RPC was 56, 8, and 4 months for each case, respectively. Eyes with clinically evident RPC had a mean AL of 24.62 - 0.11 mm, whereas in the clinically healthy fellow eyes, AL was 24.65 - 0.03 mm (p?=?0.70). The mean BCVA was 0.93 - 0.16 (range 0.80 to 1.0) in the eyes with RPC, and 1.0 in all the fellow eyes (p?=?0.70). The slit-lamp examination ruled out the presence of vitreous or anterior chamber inflammatory cells in all cases. All patients had been treated with oral steroids in a tapering regimen starting from a maximum dose of 90 mg per day (1 mg/kg/day). By the time of the SS-OCT examination, none of them was under steroid therapy (minimum 1 month after steroid cessation).

Quantitative analysis of the retina

The mean automatically measured retinal thickness of the macular area was 288.10 - 10.22 ?m in eyes with RPC and 300.30 - 7.17 ?m in the healthy fellow eyes; no statistically significant differences were evidenced (p?=?0.20). The mean automatically measured retinal thickness in the central sector of the ETDRS grid (within 500 ?m from the center of the fovea) was 257.33 - 31.53 ?m in eyes with RPC, and 269.33 - 19.75 ?m in the healthy fellow eyes; no statistically significant differences were observed (p?=?0.99). The mean retinal thicknesses of the nasal, inferior, temporal, and superior sectors automatically measured in the juxtafoveal area (500 to 1,500 ?m from the center of the fovea) and in the extrafoveal area (1,500 to 3,000 ?m from the center of the fovea) are summarized in the Table 1.
Table 1
Mean retinal thickness values per sector
Sector
Retina
Study eyes
Fellow eyes
pvalue
Central
257.33?-?31.53
269.33?-?19.76
0.827
Juxtafoveal nasal
310.00?-?23.58
316.33?-?17.95
0.658
Juxtafoveal inferior
283.67?-?24.13
289.30?-?4.62
0.825
Juxtafoveal temporal
310.67?-?10.69
327.70?-?9.50
0.127
Juxtafoveal superior
266.00?-?8.88
271.70?-?24.79
0.827
Extrafoveal nasal
308.00?-?11.27
324.00?-?5.00
0.127
Extrafoveal inferior
270.33?-?15.04
289.99?-?32.05
0.275
Extrafoveal temporal
316.33?-?10.02
328.70?-?6.66
0.127
Extrafoveal superior
270.33?-?6.11
287.00?-?18.52
0.127
Mean
288.07?-?10.22
300.30?-?7.17
0.127

Quantitative analysis of the choroid

The mean automatically measured choroidal thickness of the entire macular region was 248.60 - 128.40 ?m in eyes with RPC, and 255.10 - 123.60 ?m in the healthy fellow eyes; no statistically significant differences were observed (p?=?0.99). The mean automatically measured choroidal thickness in the central sector of the ETDRS grid (within 500 ?m from the center of the fovea) was 260.70 - 140.60 ?m in the study eyes, and 262.30 - 123.10 ?m in the healthy fellow eyes; no statistically significant differences were evidenced (p?=?0.99). The mean automatically measured choroidal thickness in the juxtafoveal sectors (500 to 1,500 ?m from the center of the fovea) and extrafoveal sectors (1,500 to 3,000 ?m from the center of the fovea) showed no significant differences between the affected eyes and the healthy fellow eyes as reported in the Table 2.
Table 2
Mean choroidal thickness values per sector
Sector
Choroid
Study eyes
Fellow eyes
pvalue
Central
260.67?-?140.61
262.33?-?123.09
0.827
Juxtafoveal nasal
260.68?-?137.70
247.33?-?142.42
0.658
Juxtafoveal inferior
260.69?-?76.36
198.00?-?122.39
0.827
Juxtafoveal temporal
260.70?-?155.02
256.33?-?134.93
0.827
Juxtafoveal superior
260.71?-?163.02
238.67?-?135.55
0.827
Extrafoveal nasal
260.72?-?146.32
271.67?-?117.46
0.827
Extrafoveal inferior
260.73?-?132.20
250.00?-?113.22
0.513
Extrafoveal temporal
260.74?-?124.94
287.67?-?125.64
0.827
Extrafoveal superior
260.75?-?100.37
283.67?-?129.08
0.827
Mean
260.76?-?128.44
255.07?-?123.62
0.827

Discussion

The differential diagnosis of RPC includes mainly APMPPE and serpiginous choroiditis. These diseases share similar clinical and angiographic characteristics, with creamy lesions that exhibit early hypofluorescence in the fluorescein angiography with later staining [1]. The different clinical course and the atypical distribution of the lesions in patients with RPC may assist its diagnosis, although some cases may need a long-term follow-up to be able to differentiate them.
The angiographic characteristics in patients with acute RPC reveal a presumed choroidal involvement, which represent a common finding in cases of posterior uveitis. Changes in the choroidal thickness have been reported in many inflammatory diseases as Vogt-Koyanagi-Harada disease [8], Beh et uveitis [9] or posterior scleritis [10]. To the best of our knowledge, there are no reports in the literature regarding the influence of RPC, APMPPE, or serpiginous choroiditis in the choroidal tissue.

Conclusions

We studied the retinal and choroidal thickness of the macula in cases of unilateral RPC with macular involvement in a quiescent stage. Our results did not evidence any difference in the retinal or choroidal thickness in the macular area when comparing the affected eye with the fellow healthy eye. We hypothesized that this characteristic may help in the differential diagnosis with serpiginous choroiditis, since cases of serpiginous choroiditis may lead to severe atrophic legacy not only in the retina but also in the choroid. This relative sparing of the choroid in RPC may be related to the degree of the inflammatory reaction on the tissue.
The limitations of our study include the short number of patients and follow-up. There is also a lack of reports regarding the choroidal thickness in cases of posterior uveitis. Further studies are warranted in order to confirm the sparing of the choroidal thickness in cases of RPC. These data might be useful in the differentiation of plaque-like white dot syndromes as RPC, APMPPE, and serpiginous choroiditis.

Anknowledgements

We thank Nestor Garca Marn for his valuable help in the examination of patients and Dr. M Dolores Pinazo Durn for the evaluation and critical analysis of the study design.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Competing interests

RDM received research grants from Alcon, Allergan, Bayer, Heidelberg Engineering, Novartis, and Thea. RGP is a consultant to Alcon, Bayer, and Novartis and received research grants from Alcon, Allergan, Bayer, Heidelberg Engineering, Novartis, Sensimed, and Thea. The other authors declare that they have no competing interests.

Authors' contributions

All authors have made substantial contributions to conception and design of the study or acquisition, analysis, and interpretation of data; have been involved in drafting the manuscript or revising it critically for important intellectual content; have given final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Literatur
1.
Zurück zum Zitat Jones BE, Jampol LM, Yannuzzi LA, Tittl M, Johnson MW, Han DP, Davis JL, Williams DF: Relentless placoid chorioretinitis: a new entity or an unusual variant of serpiginous chorioretinitis? Arch Ophthalmol 2000, 118: 931–938. 10.1001/archopht.118.4.584CrossRefPubMed Jones BE, Jampol LM, Yannuzzi LA, Tittl M, Johnson MW, Han DP, Davis JL, Williams DF: Relentless placoid chorioretinitis: a new entity or an unusual variant of serpiginous chorioretinitis? Arch Ophthalmol 2000, 118: 931–938. 10.1001/archopht.118.4.584CrossRefPubMed
2.
Zurück zum Zitat Veronese C, Marcheggiani EB, Tassi F, Pichi F, Morara M, Ciardella AP: Early autofluorescence findings of relentless placoid chorioretinitis. Retina 2014, 34: 625–627. 10.1097/IAE.0b013e3182a487d5CrossRefPubMed Veronese C, Marcheggiani EB, Tassi F, Pichi F, Morara M, Ciardella AP: Early autofluorescence findings of relentless placoid chorioretinitis. Retina 2014, 34: 625–627. 10.1097/IAE.0b013e3182a487d5CrossRefPubMed
3.
Zurück zum Zitat Yeh S, Lew JC, Wong WT, Nussenblatt RB: Relentless placoid chorioretinitis associated with central nervous system lesions treated with mycophenolate mofetil. Arch Ophthalmol 2009, 127: 341–343. 10.1001/archophthalmol.2009.12CrossRefPubMed Yeh S, Lew JC, Wong WT, Nussenblatt RB: Relentless placoid chorioretinitis associated with central nervous system lesions treated with mycophenolate mofetil. Arch Ophthalmol 2009, 127: 341–343. 10.1001/archophthalmol.2009.12CrossRefPubMed
4.
Zurück zum Zitat Choma M, Sarunic M, Yang C, Izatt J: Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express 2003, 11: 2183–2189. 10.1364/OE.11.002183CrossRefPubMed Choma M, Sarunic M, Yang C, Izatt J: Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express 2003, 11: 2183–2189. 10.1364/OE.11.002183CrossRefPubMed
5.
Zurück zum Zitat Unterhuber A, Povazay B, Hermann B, Sattmann H, Chavez-Pirson A, Drexler W: In vivo retinal optical coherence tomography at 1040 nm - enhanced penetration into the choroid. Opt Express 2005, 13: 3252–3258. 10.1364/OPEX.13.003252CrossRefPubMed Unterhuber A, Povazay B, Hermann B, Sattmann H, Chavez-Pirson A, Drexler W: In vivo retinal optical coherence tomography at 1040 nm - enhanced penetration into the choroid. Opt Express 2005, 13: 3252–3258. 10.1364/OPEX.13.003252CrossRefPubMed
6.
Zurück zum Zitat Agawa T, Miura M, Ikuno Y, Makita S, Fabritius T, Iwasaki T, Goto H, Nishida K, Yasuno Y: Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2011, 249: 1485–1492. 10.1007/s00417-011-1708-7CrossRefPubMed Agawa T, Miura M, Ikuno Y, Makita S, Fabritius T, Iwasaki T, Goto H, Nishida K, Yasuno Y: Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2011, 249: 1485–1492. 10.1007/s00417-011-1708-7CrossRefPubMed
7.
Zurück zum Zitat Hirata M, Tsujikawa A, Matsumoto A, Hangai M, Ooto S, Yamashiro K, Akiba M, Yoshimura N: Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci 2011, 52: 4971–4978. 10.1167/iovs.11-7729CrossRefPubMed Hirata M, Tsujikawa A, Matsumoto A, Hangai M, Ooto S, Yamashiro K, Akiba M, Yoshimura N: Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci 2011, 52: 4971–4978. 10.1167/iovs.11-7729CrossRefPubMed
8.
Zurück zum Zitat Nakayama M, Keino H, Okada AA, Watanabe T, Taki W, Inoue M, Hirakata A: Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease. Retina 2012, 32: 2061–2069. 10.1097/IAE.0b013e318256205aCrossRefPubMed Nakayama M, Keino H, Okada AA, Watanabe T, Taki W, Inoue M, Hirakata A: Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease. Retina 2012, 32: 2061–2069. 10.1097/IAE.0b013e318256205aCrossRefPubMed
9.
Zurück zum Zitat Kim M, Kim H, Kwon HJ, Kim SS, Koh HJ, Lee SC: Choroidal thickness in Behcet's uveitis: an enhanced depth imaging-optical coherence tomography and its association with angiographic changes. Invest Ophthalmol Vis Sci 2013, 54: 6033–6039. 10.1167/iovs.13-12231CrossRefPubMed Kim M, Kim H, Kwon HJ, Kim SS, Koh HJ, Lee SC: Choroidal thickness in Behcet's uveitis: an enhanced depth imaging-optical coherence tomography and its association with angiographic changes. Invest Ophthalmol Vis Sci 2013, 54: 6033–6039. 10.1167/iovs.13-12231CrossRefPubMed
10.
Zurück zum Zitat Uchihori H, Nakai K, Ikuno Y, Gomi F, Hashida N, Jo Y, Nishida K: Choroidal observations in posterior scleritis using high-penetration optical coherence tomography. Int Ophthalmol 2014,34(4):937–943. doi:10.1007/s10792–013–9894–4 10.1007/s10792-013-9894-4CrossRefPubMed Uchihori H, Nakai K, Ikuno Y, Gomi F, Hashida N, Jo Y, Nishida K: Choroidal observations in posterior scleritis using high-penetration optical coherence tomography. Int Ophthalmol 2014,34(4):937–943. doi:10.1007/s10792–013–9894–4 10.1007/s10792-013-9894-4CrossRefPubMed
Metadaten
Titel
Macular retinal and choroidal thickness in unilateral relentless placoid chorioretinitis analyzed by swept-source optical coherence tomography
verfasst von
Rosa Dolz-Marco
Álvaro Rodríguez-Ratín
Pablo Hernández-Martínez
Isabel Pascual-Camps
María Andreu-Fenoll
Roberto Gallego-Pinazo
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Ophthalmic Inflammation and Infection / Ausgabe 1/2014
Elektronische ISSN: 1869-5760
DOI
https://doi.org/10.1186/s12348-014-0024-x

Weitere Artikel der Ausgabe 1/2014

Journal of Ophthalmic Inflammation and Infection 1/2014 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.